Trump Administration's New Tariffs on Pharmaceutical Imports Pose Challenges for Biotech Companies

The Trump administration's new 100% tariffs on pharmaceutical imports and their active ingredients, which came into effect at the end of September, are creating significant challenges for biotech companies. While larger drug manufacturers in the U.S. are often exempt, smaller biotech firms are reportedly struggling to secure similar exemptions, impacting their ability to operate and obtain necessary ingredients.